Injectable perlecan domain 1-hyaluronan microgels potentiate the cartilage repair effect of BMP2 in a murine model of early osteoarthritis

Biomedical Materials

Volumn 7, Issue 2, 2012, Pages

  Srinivasan, Padma P ^a   McCoy, Sarah Y ^a   Jha, Amit K ^a,c   Yang, Weidong ^a,d   Jia, Xinqiao ^a   Farach Carson, Mary C ^a,b   Kirn Safran, Catherine B ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b RICE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; COLLAGEN; ENCODING (SYMBOLS); GELS; GENE EXPRESSION; GLYCOPROTEINS; MAMMALS; ORGANIC ACIDS;

ANIMAL MODEL; ARTICULAR CARTILAGES; BONE MORPHOGENETIC PROTEIN-2; CARTILAGE REPAIR; CONTROLLED RELEASE; GLYCOSAMINOGLYCANS; HEPARAN SULFATES; HYALURONIC ACIDS; IMMUNOSTAINING; IN-VIVO; INTRA-ARTICULAR INJECTION; KNEE INJURY; MATRIX REPAIR; MATRIX SYNTHESIS; MICRO-GELS; MRNA LEVEL; MURINE MODEL; PERLECAN; PROTEOGLYCANS; RATE LIMITING; THERAPEUTIC AGENTS; TYPE II COLLAGENS; TYPE X COLLAGEN;

CARTILAGE;

AGGRECAN; COLLAGEN TYPE 10; COLLAGEN TYPE 2; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HYALURONIC ACID; MESSENGER RNA; PERLECAN; PERLECAN DOMAIN 1; PROTEOGLYCAN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; TRANSFERASE; UNCLASSIFIED DRUG; XYLOSYLTRANSFERASE 1; BMP2 PROTEIN, MOUSE; BONE MORPHOGENETIC PROTEIN 2; PROTEOHEPARAN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE INJURY; CARTILAGE MATRIX; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; GEL; GENE EXPRESSION; GLYCOSAMINOGLYCAN METABOLISM; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INJECTION; KNEE INJURY; KNEE OSTEOARTHRITIS; MOUSE; NONHUMAN; TREATMENT OUTCOME; ANIMAL; C57BL MOUSE; CARTILAGE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; HYDROGEL; INTRAARTICULAR DRUG ADMINISTRATION; OSTEOARTHRITIS; PATHOLOGY; SYNTHESIS;

ANIMALIA; MURINAE; MUS;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CARTILAGE; DELAYED-ACTION PREPARATIONS; HEPARAN SULFATE PROTEOGLYCANS; HYALURONIC ACID; HYDROGELS; INJECTIONS, INTRA-ARTICULAR; MICE; MICE, INBRED C57BL; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 84859397944     PISSN: 17486041     EISSN: 1748605X     Source Type: Journal    
DOI: 10.1088/1748-6041/7/2/024109     Document Type: Article

References (47)

1. van der Kraan P M, Buma P, van Kuppevelt T and van den Berg W B 2002 Interaction of chondrocytes, extracellular matrix and growth factors: relevance for articular cartilage tissue engineering Osteoarthritis Cartilage 10 631-7 (Pubitemid 34993949)
2. Jha A K, Yang W, Kirn-Safran C B, Farach-Carson M C and Jia X 2009 Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release Biomaterials 30 6964-75
3. Blaney Davidson E N, Vitters E L, van Lent P L, van de Loo F A, van den Berg W B and van der Kraan P M 2007 Elevated extracellular matrix production and degradation upon bone morphogenetic protein-2 (BMP-2) stimulation point toward a role for BMP-2 in cartilage repair and remodeling Arthritis Res. Ther. 9 R102
4. Quintana L, Muinos T F, Genove E, Del Mar Olmos M, Borros S and Semino C E 2009 Early tissue patterning recreated by mouse embryonic fibroblasts in a three-dimensional environment Tissue Eng. A 15 45-54
5. Hall B K and Miyake T 2000 All for one and one for all: condensations and the initiation of skeletal development Bioessays 22 138-47 (Pubitemid 30092080)
6. Ducy P and Karsenty G 2000 The family of bone morphogenetic proteins Kidney Int. 57 2207-14 (Pubitemid 30340719)
7. Schmitt B, Ringe J, Haupl T, Notter M, Manz R, Burmester G R, Sittinger M and Kaps C 2003 BMP2 initiates chondrogenic lineage development of adult human mesenchymal stem cells in high-density culture Differentiation 71 567-77 (Pubitemid 38091099)
8. Blaney Davidson E N, Vitters E L, van der Kraan P M and van den Berg W B 2006 Expression of transforming growth factor-beta (TGFbeta) and the TGFbeta signalling molecule SMAD-2P in spontaneous and instability-induced osteoarthritis: role in cartilage degradation, chondrogenesis and osteophyte formation Ann. Rheum. Dis. 65 1414-21 (Pubitemid 44629115)
9. Dell'Accio F, De Bari C, El Tawil N M, Barone F, Mitsiadis T A, O'Dowd J and Pitzalis C 2006 Activation of WNT and BMP signaling in adult human articular cartilage following mechanical injury Arthritis Res. Ther. 8 R139
10. Nimni M E 1997 Polypeptide growth factors: targeted delivery systems Biomaterials 18 1201-25 (Pubitemid 27390300)
11. Babensee J E, McIntire L V and Mikos A G 2000 Growth factor delivery for tissue engineering Pharm. Res. 17 497-504 (Pubitemid 30416385)
12. Rodgers K D, Sasaki T, Aszodi A and Jacenko O 2007 Reduced perlecan in mice results in chondrodysplasia resembling Schwartz-Jampel syndrome Hum. Mol. Genet. 16 515-28 (Pubitemid 46522614)
13. Farach-Carson M C and Carson D D 2007 Perlecan - a multifunctional extracellular proteoglycan scaffold Glycobiology 17 897-905 (Pubitemid 47423879)
14. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell J R and Yamada Y 1999 Perlecan is essential for cartilage and cephalic development Nat. Genet. 23 354-8 (Pubitemid 29526437)
15. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R and Fassler R 1999 Perlecan maintains the integrity of cartilage and some basement membranes J. Cell Biol. 147 1109-22
16. Kirn-Safran C, Farach-Carson M C and Carson D D 2009 Multifunctionality of extracellular and cell surface heparan sulfate proteoglycans Cell Mol. Life Sci. 66 3421-34
17. French M M, Gomes R R Jr, Timpl R, Hook M, Czymmek K, Farach-Carson M C and Carson D D 2002 Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I J. Bone Miner. Res. 17 48-55 (Pubitemid 33150996)
18. Yang W D, Gomes R R Jr, Alicknavitch M, Farach-Carson M C and Carson D D 2005 Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds Tissue Eng. 11 76-89 (Pubitemid 40515177)
19. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogamo A and Kamijo R 2003 Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins J. Biol. Chem. 278 43229-35 (Pubitemid 37345942)
20. Ruppert R, Hoffmann E and Sebald W 1996 Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity Eur. J. Biochem. 237 295-302 (Pubitemid 26110301)
21. Yang W, Gomes R R, Brown A J, Burdett A R, Alicknavitch M, Farach-Carson M C and Carson D D 2006 Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices Tissue Eng. 12 2009-24 (Pubitemid 44162858)
22. Knudson C B and Knudson W 2001 Cartilage proteoglycans Semin. Cell Dev. Biol. 12 69-78
23. Kirchner M and Marshall D 2006 A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the treatment of osteoarthritis of the knee Osteoarthritis Cartilage 14 154-62 (Pubitemid 43079312)
24. Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten F P, Scott D L, Bailleul F and Pavelka K 2010 Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial Ann. Rheum. Dis. 69 113-9
25. Jazrawi L M and Rosen J 2011 Intra-articular hyaluronic acid: potential treatment of younger patients with knee injury and/or post-traumatic arthritis Phys. Sportsmed 39 107-13
26. van der Kraan P M, Vitters E L, van de Putte L B and van den Berg W B 1989 Development of osteoarthritic lesions in mice by 'metabolic' and 'mechanical' alterations in the knee joints Am. J. Pathol. 135 1001-14 (Pubitemid 20026520)
27. Costell M, Mann K, Yamada Y and Timpl R 1997 Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides Eur. J. Biochem. 243 115-21 (Pubitemid 27060392)
28. Kang Q K, LaBreck J C, Gruber H E and An Y H 2003 Histological techniques for decalcified bone and cartilage Handbook of Histology Methods for Bone and Cartilage ed Y H An and K L Martin (Totowa: Humana Press Inc.) pp 209-19
29. Glasson S S, Blanchet T J and Morris E A 2007 The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse Osteoarthritis Cartilage 15 1061-9 (Pubitemid 47387036)
30. Nagase H and Kashiwagi M 2003 Aggrecanases and cartilage matrix degradation Arthritis Res. Ther. 5 94-103 (Pubitemid 36849755)
31. Kiani C, Chen L, Wu Y J, Yee A J and Yang B B 2002 Structure and function of aggrecan Cell Res. 12 19-32 (Pubitemid 135708300)
32. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A and Speleman F 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes Genome Biol. 3 RESEARCH0034
33. McDonald J 2009 Handbook of Biological Statistics (Baltimore: Sparky House Publishing)
34. Venkatesan N, Barre L, Magdalou J, Mainard D, Netter P, Fournel-Gigleux S and Ouzzine M 2009 Modulation of xylosyltransferase I expression provides a mechanism regulating glycosaminoglycan chain synthesis during cartilage destruction and repair FASEB J. 23 813-22
35. Blaney Davidson E N, Vitters E L, van Beuningen H M, van de Loo F A, van den Berg W B and van der Kraan P M 2007 Resemblance of osteophytes in experimental osteoarthritis to transforming growth factor beta-induced osteophytes: limited role of bone morphogenetic protein in early osteoarthritic osteophyte formation Arthritis Rheum. 56 4065-73 (Pubitemid 350262334)
36. Glasson S S et al 2005 Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis Nature 434 644-8 (Pubitemid 40488556)
37. Tardif G, Pelletier J P, Boileau C and Martel-Pelletier J 2009 The BMP antagonists follistatin and gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study Osteoarthritis Cartilage 17 263-70
38. van Beuningen H M, Glansbeek H L, van der Kraan P M and van den Berg W B 1998 Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation Osteoarthritis Cartilage 6 306-17 (Pubitemid 28404971)
39. Bakker A C, van de Loo F A, van Beuningen H M, Sime P, van Lent P L, van der Kraan P M, Richards C D and van den Berg W B 2001 Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation Osteoarthritis Cartilage 9 128-36 (Pubitemid 32229262)
40. Poole R et al 2010 Recommendations for the use of preclinical models in the study and treatment of osteoarthritis Osteoarthritis Cartilage 18 Suppl. 3 S10-6
41. Vlodavsky I, Miao H Q, Medalion B, Danagher P and Ron D 1996 Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor Cancer Metastasis Rev. 15 177-86 (Pubitemid 26236115)
42. Whitelock J M, Melrose J and Iozzo R V 2008 Diverse cell signaling events modulated by perlecan Biochemistry 47 11174-83
43. Li S et al 2010 Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity J. Biol. Chem. 285 36645-55
44. Ohkawara B, Iemura S, ten Dijke P and Ueno N 2002 Action range of BMP is defined by its N-terminal basic amino acid core Curr. Biol. 12 205-9 (Pubitemid 34122375)
45. Otto T C, Bowers R R and Lane M D 2007 BMP-4 treatment of C3H10T1/2 stem cells blocks expression of MMP-3 and MMP-13 Biochem. Biophys. Res. Commun. 353 1097-104 (Pubitemid 46080411)
46. Maroudas A, Palla G and Gilav E 1992 Racemization of aspartic acid in human articular cartilage Connect. Tissue Res. 28 161-9
47. Lohmander L S, Englund P M, Dahl L L and Roos E M 2007 The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis Am. J. Sports Med. 35 1756-69 (Pubitemid 47476065)